Mahkam Zanganeh - Apr 8, 2025 Form 4 Insider Report for Summit Therapeutics Inc. (SMMT)

Role
Co-Chief Executive Officer, Director, 10%+ Owner
Signature
/s/ Mahkam Zanganeh
Stock symbol
SMMT
Transactions as of
Apr 8, 2025
Transactions value $
$6,296,387
Form type
4
Date filed
4/9/2025, 05:19 PM
Previous filing
Feb 11, 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SMMT Common Stock Exercise of in-the-money or at-the-money derivative security $6.3M +3.99M +0.72% $1.58 556M Apr 8, 2025 By Spouse F1, F2
holding SMMT Common Stock 10.2M Apr 8, 2025 By the Shaun Zanganeh Irrevocable Trust, with the Reporting Person as Trustee F2
holding SMMT Common Stock 25.5M Apr 8, 2025 By the Mahkam Zanganeh Revocable Trust, with the Reporting Person as Trustee F2
holding SMMT Common Stock 50K Apr 8, 2025 Immediate family member F2
holding SMMT Common Stock 31K Apr 8, 2025 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SMMT Warrant (right to buy) Exercise of in-the-money or at-the-money derivative security $0 +3.99M $0.00 0 Apr 8, 2025 Common Stock 3.99M $1.58 By Spouse F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On April 8, 2025, the Reporting Person's spouse exercised warrants to purchase an aggregate of 3,985,055 shares of the Issuer's common stock at an exercise price of $1.58 per share
F2 The Reporting Person disclaims beneficial ownership of these securities, except to the extent of her pecuniary interest therein, if any, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 or for any other purpose.